Dr. Reddy's in the news

Grab the opportunity when it comes

It is time for beneficiaries of liberalization to lead

Dr. Reddy's prescription to stay ahead of the generic pack

The company has differentiated itself by focusing on internal processes and staying away from costly acquisitions. Now, it has other plans to fend off the competition.

A new prescription

Tectonic changes in the US generic drugs market is causing huge shifts in Indian pharma’s strategies as well.

Influence is a leadership tool

Leaders can garner respect from others and achieve set targets by effectively influencing colleagues (by Saumen Chakraborty - President and Global Chief of Quality, HR& IT at Dr. Reddy’s Laboratories Ltd).

Affordable innovative drugs still our priority

For Satish Reddy, joining Dr Reddy's Labs (DRL) was not a planned move, and certainly not for which he was being groomed formally.

Dr. Reddy’s chalks out plan to improve India performance

India's second largest pharmaceutical company, dr. Reddy's Laboratories, is on the verge of giving final touches to a comprehensive strategy to boost the much needed growth in the Indian market

Leaderspeak – GV Prasad

Dr. Reddy’s lines up strong drug pipeline

Pharmaceuticals major Dr. Reddy’s Laboratories sees a busy year ahead as it plans to launch 15-16 products in the US market, which is likely to contribute one-third to its revenues.

India’s Dr. Reddy’s gets US nod for osteoporosis drug

Indian drugmaker Dr Reddy's Laboratories has received U.S. Food and Drug Administration's approval for selling ibandronate sodium tablets used to treat osteoporosis, the regulator's website showed on Thursday.

Dr Reddy's plans multi-pronged strategy to build Russian business

Dr. Reddy's appears set for a significant scale-up in Russia, including plans for a joint venture manufacturing facility, a prescription and OTx (prescription plus switch over-the-counter) thrust and a new in-licensing pact with Novartis deepening its eng

Dr. Reddy's to replace DLF in Sensex

The Bombay Stock Exchange (BSE) said today that pharma major Dr Reddy's Laboratories will replace DLF in the benchmark 30-share Sensex.

SMT is an empowered Multi-skilled and energetic team

Developing an internal talent pool is important for organizations as it represents significant savings in terms of costs and on boarding time.

Dr Reddy's: May Change Hedging Policy If Dollar Rises Sharply

Dr. Reddy's Laboratories Ltd. may consider revising its hedging policy if the U.S. dollar gains sharply above the upper end of the Indian generic drug maker's expectations, its chief financial officer said.

Career Journal: Hey Boss! Don't Assume Your Top Performers Are Happy

Can good performance be taken as a parameter to judge an employee’s happiness? Not really, says Saumen Chakraborty, president and global chief of human resources, quality and information technology at Dr. Reddy’s Laboratories Ltd.

In Good Health

Anji Reddy may be unwell. But with a succession plan in place, no one is worried about the future of the company he founded

Stage set for easy money

We are returning to a phase of more predictability, and things have improved on the inflation front.

Dr. Reddy's eyes biosimilars expansion and rejigs research focus

Dr. Reddy's is in talks with potential partners to push into regulated markets in the biosimilars segment.